An indemnity fund established to compensate those who suffer from complications following Covid-19 vaccination has granted HK$2 million over one post-jab death case, the first in such cases.
The case saw a 66-year-old woman die in July last year, 16 days after receiving her first BioNTech vaccine
A full autopsy report indicated that she died from myocarditis. Other investigation results also showed that the deceased was suffering from pneumonia when she died.
The government’s Expert Committee on Clinical Events Assessment Following COVID
-19 Immunization has concluded the case as “indeterminate” after failing to establish a causal relationship between the deceased’s outcome and the vaccination.
In accordance with the terms and conditions set out by the government under the indemnity fund, death payout is still granted to the case, although it was assessed by the Expert Committee as causality indeterminate.
As of April 23, the indemnity fund has received 843 applications, including 31 for deaths. The Expert Committee has completed causality assessments for 551 of those cases.
Out of those, 328 cases were concluded to be “consistent with casual association with immunization” or “indeterminate” and 223 cases were concluded to be “inconsistent with causal association with immunization” or “unclassifiable”.
The fund has granted a total of HK$33 million to 242 cases, including the post-jab death case. The other 241 whose applications were granted are post-jab injury cases that involve the vaccine
recipients developing common side effects, including Anaphylaxis, Bell’s Palsy, and Erythema Multiforme.